The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1618-7601
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ; day:9 ; month:3 ; year:2018 ; pages:1-10
The European journal of health economics ; (9.3.2018), 1-10
- Urheber
- Beteiligte Personen und Organisationen
-
Hertel, Nadine
Ellis, John
Morais, Edith
Johnson, Helen
Philips, Zoe
Roskell, Neil
Walker, Andrew
Lee, Dawn
SpringerLink (Online service)
- DOI
-
10.1007/s10198-018-0964-4
- URN
-
urn:nbn:de:1111-2018051328840
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meng, Yang
- Hertel, Nadine
- Ellis, John
- Morais, Edith
- Johnson, Helen
- Philips, Zoe
- Roskell, Neil
- Walker, Andrew
- Lee, Dawn
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma